ÂÜÀòÂÒÂ×

Arantxa is an expert in infectious diseases drug development with over 15 years of broad biopharmaceutical experience including clinical development program leadership, clinical operations, and pharmacovigilance.

Before joining Atea, Arantxa she served as Vice President, Pharmacovigilance and Medical Affairs at Biohaven Pharmaceuticals. Prior to that, Arantxa served as Vice President, Global Head of Clinical Program Execution, Site Head of the Roche NY Innovation Center and as Global Head of Translational Medicine, Infectious Diseases at F. Hoffmann-La Roche. Arantxa began her career in drug discovery and development at Bristol-Myers Squibb where she rose through a series of clinical leadership positions to become Group Director, Global Clinical Research, Virology.

Arantxa holds an M.D. from the Santander School of Medicine and completed her residency in Pediatrics and a fellowship in Pediatric Infectious Diseases at the Mount Sinai School of Medicine, where she remained as faculty. During her academic tenure, Arantxa’s NIH-funded laboratory research focused on mechanisms of pathogenesis of respiratory viruses.